Interpace Diagnostics Group (NASDAQ:IDXG)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Tuesday, AnalystRatings.com reports.
Several other equities research analysts also recently issued reports on IDXG. Oppenheimer initiated coverage on Interpace Diagnostics Group in a report on Thursday, September 26th. They issued an “outperform” rating and a $3.00 price target for the company. Maxim Group set a $2.00 price objective on Interpace Diagnostics Group and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, ValuEngine raised Interpace Diagnostics Group from a “sell” rating to a “hold” rating in a research report on Tuesday, December 3rd.
Interpace Diagnostics Group stock opened at $8.28 on Tuesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.19 and a current ratio of 1.19. The firm has a market cap of $31.28 million, a P/E ratio of -1.45 and a beta of 2.16. The business’s fifty day moving average is $1.55 and its two-hundred day moving average is $0.96. Interpace Diagnostics Group has a 52 week low of $3.81 and a 52 week high of $11.20.
Interpace Diagnostics Group (NASDAQ:IDXG) last released its earnings results on Wednesday, November 13th. The business services provider reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). The company had revenue of $7.73 million during the quarter, compared to the consensus estimate of $10.00 million. Interpace Diagnostics Group had a negative return on equity of 58.48% and a negative net margin of 77.55%. On average, equities research analysts predict that Interpace Diagnostics Group will post -4.6 earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IDXG. River & Mercantile Asset Management LLP bought a new stake in Interpace Diagnostics Group during the 2nd quarter worth approximately $468,000. Perkins Capital Management Inc. lifted its stake in Interpace Diagnostics Group by 22.5% in the third quarter. Perkins Capital Management Inc. now owns 2,360,385 shares of the business services provider’s stock valued at $1,876,000 after purchasing an additional 433,135 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in Interpace Diagnostics Group by 98.0% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 44,750 shares of the business services provider’s stock valued at $32,000 after purchasing an additional 22,150 shares during the last quarter.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
See Also: Roth IRA
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.